The impacts of the Renin-Angiotensin-Aldosterone System (RAAS) blockade medicine on COVID-19 are unclear, with evidence showing RAAS blockade increased ACE2 expression and COVID-19 infection risk (29). The gene discussed is ACE2; the disease is COVID-19.